Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1985
Pharmacology and receptor binding of atrial natriuretic factor in vascular smooth muscleR J Winquist, M A Napier, R L Vandlen, et al.Journal of Cardiovascular Pharmacology|February 1, 1995
Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agentsJ J Lynch, E P Baskin, E M Nutt, et al.The Journal of Pharmacology and Experimental Therapeutics|January 1, 1989
Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscleR J Winquist, L A Heaney, A A Wallace, et al.Journal of Cardiovascular Pharmacology|September 11, 1991
Effects of new and potent methanesulfonanilide class III antiarrhythmic agents on myocardial refractoriness and contractility in isolated cardiac muscleE P Baskin, C M Serik, A A Wallace, et al.Cardiovascular Research|February 13, 2001
Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesisJ C Hershey, E P Baskin, J D Glass, et al.The Journal of Pharmacology and Experimental Therapeutics|April 1, 1995
Cardiac electrophysiologic and antiarrhythmic actions of tedisamilA A Wallace, R F Stupienski, E P Baskin, et al.The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]J J Lynch, A A Wallace, R F Stupienski, et al.The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agentJ J Lynch, A A Wallace, L H Van der Gaag, et al.Journal of Medicinal Chemistry|May 23, 1997
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacyT J Tucker, W C Lumma, S D Lewis, et al.Journal of Medicinal Chemistry|November 14, 1997
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 positionT J Tucker, W C Lumma, S D Lewis, et al.Pageof 3